Drugs Containing Excipient (Inactive Ingredient) METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER

Branded drugs containing METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	DELZICOL	mesalamine	0023-5853	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER
Allergan Inc	ASACOL HD	mesalamine	0023-5901	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER
Allergan Inc	KADIAN	morphine sulfate	0023-6011	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER

Generic drugs containing METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER excipient

Company	Ingredient	NDC	Excipient
Allergan Inc	mesalamine	0023-5853	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER
Allergan Inc	mesalamine	0023-5901	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER
Allergan Inc	morphine sulfate	0023-6011	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER

Market Dynamics and Financial Trajectory for Methacrylic Acid - Methyl Methacrylate Copolymer

Last updated: February 20, 2026

What Are the Key Drivers of Demand?

The demand for methacrylic acid and methyl methacrylate (MMA) copolymers predominantly stems from the pharmaceutical excipient sector. These copolymers are valued for their film-forming, binding, and controlled-release characteristics.

Pharmaceutical Sector Growth

• The global pharmaceutical industry expanded at a CAGR of 3.3% from 2018 to 2022, reaching $1.42 trillion.[1]
• Excipients including methacrylic copolymers constitute roughly 10% of overall formulation costs, with demand linked directly to new drug development.
• Oral controlled-release formulations account for approximately 50% of methacrylic copolymer use in pharmaceuticals.[2]

Key Developments Elevating Demand

• Increase in chronic disease treatments requiring sustained-release drugs.
• Shift towards specialized drug delivery systems targeting specific release profiles.
• Regulatory standards favoring controlled-release formulations to improve therapeutic efficacy.

Market Segments and Application Trends

Geographical Distribution

Region	Share 2022	Growth Rate (2023–2028)	Major Players
North America	36%	4.1%	Dow Chemical, Evonik
Europe	28%	3.9%	Shin-Etsu, DOW
Asia-Pacific	30%	7.2%	Mitsubishi Chemical, LG
Rest of World	6%	3.0%	Various

Primary Applications

• Controlled-release oral dosage forms: 55%
• Film coatings: 25%
• Topical and dermatological formulations: 10%
• Other: 10%

Industry Trends

Price stability remains a concern due to raw material cost fluctuations. The rise of biosimilars and generic drugs increases the volume but pressures profit margins. The adoption of bio-based alternatives threatens traditional petrochemical-based copolymers.

Price Trends and Cost Factors

Raw Material Costs

• Methacrylic acid prices increased by approximately 15% from 2021 to 2022, driven by rising crude oil prices.
• Methyl methacrylate (MMA) typically accounts for 40–50% of total manufacturing costs of the copolymer.
• Prices for MMA fluctuated between $1.20 and $2.05 per pound in 2022.[3]

Production and Supply Chain Dynamics

• Oversupply of MMA from Asian manufacturers led to price drops in 2019–2020, stabilizing in 2021.
• Raw material supply disruptions due to geopolitical tensions, e.g., U.S.-China trade tension, impacted availability.

Pricing Projections

• The average selling price of methacrylic copolymers is projected to grow at approximately 2.5% annually through 2028.
• Price pressures from raw material volatility are expected to persist, influencing profit margins.

Competitive Landscape

Major producers of methacrylic copolymers include:

• Evonik Industries
• Dow Chemical
• Shin-Etsu Chemical
• Mitsubishi Chemical
• LG Chemical

New entrants focus on bio-based and alternative monomers to meet regulatory and sustainability demands.

Innovation and R&D

• Companies invest in developing bio-derived methyl methacrylate to appeal to environmentally conscious markets.
• Formulation improvements aim to enhance drug release control, stability, and compatibility with active pharmaceutical ingredients.

Regulatory Environment

• FDA and EMA regulations impact excipient approval and manufacturing practices.
• The Pharmacopoeia monograph standards specify purity, residual monomer limits, and packaging requirements.
• Stringent quality control increases production costs but ensures safety and efficacy.

Financial Outlook

Revenue Projections

• The global pharmaceutical excipient market valued at approximately $3.5 billion in 2022.[4]
• Methacrylic copolymers represent about 6–8% of this market, translating to roughly $210–$280 million in 2022.
• Compound annual growth rate (CAGR) projected at 4.2% from 2023 to 2028, reaching approximately $340 million by 2028.[5]

Profitability Margins

• Gross margins for producers fluctuate between 20–30%, influenced heavily by raw material costs.
• Higher-margin innovations, such as bio-based copolymers, hold margins above 35%.

Risks and Challenges

• Raw material price volatility
• Regulatory hurdles delaying product approvals
• Competition from alternative excipients and bio-derived polymers
• Supply chain disruptions

Key Takeaways

• Rising demand from controlled-release pharmaceuticals drives market growth.
• Raw material cost fluctuations significantly impact profit margins.
• Geographical expansion, especially in Asia-Pacific, offers growth opportunities.
• Companies investing in bio-based alternatives seek to mitigate regulatory and sustainability risks.
• Price stabilization due to supply-demand balance is anticipated in the medium term.

FAQs

1. What is the primary use of methacrylic acid-methyl methacrylate copolymers in pharmaceuticals?
They are mainly used as film-forming agents for controlled-release drug formulations and coatings.

2. How do raw material costs influence the market?
Fluctuations in methacrylic acid and MMA prices directly affect production costs and profit margins.

3. Which regions are experiencing the fastest growth?
Asia-Pacific leads with a projected CAGR of 7.2%, driven by expanding pharmaceutical manufacturing capacities.

4. Are bio-based alternatives impacting the market?
Yes, bio-derived methyl methacrylate and copolymers are emerging, responding to sustainability demands.

5. What are the biggest risks for market participants?
Raw material volatility, regulatory delays, and competition from alternative excipients.

References

[1] IQVIA, 2022. Global Pharmaceutical Market Reports.
[2] MarketsandMarkets, 2023. Pharmaceutical Excipients Market by Type, Application, Region – Global Forecast.
[3] ICIS Chemical Economics Handbook, 2022. Methyl Methacrylate Price Trends.
[4] Grand View Research, 2022. Excipients Market Size & Share.
[5] Mordor Intelligence, 2023. Pharmaceutical Excipients Market Forecast.